The average gap between NHI prices and the market prices of listed medicines in Japan stood at a preliminary 5.2%…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Development of Antibody Drugs Accelerating in the Field of Asthma; First New Option Could Be Available as Early as 2016
August 5, 2014
-
REGULATORY MHLW to Fund Research Aimed at Obtaining Additional Indications for Intractable and Orphan Diseases for Existing Drugs
August 4, 2014
-
REGULATORY PAFSC First Committee Backs Approval of MSD’s Insomnia Treatment
August 4, 2014
-
REGULATORY Improvement Order Issued to Novartis over Delayed ADR Reporting
August 1, 2014
-
BUSINESS Nissan Chemical Files Livalo Patent Suit against Sawai in US
July 31, 2014
-
REGULATORY Regulatory Review Trend in Japan Signals Pharmas’ Shift to Cancer Drugs: Jiho Tally
July 30, 2014
-
REGULATORY NIBIO Initiates Support for Applied Research on 15 Promising Drug Seeds with Goal of First Licensing Agreement by FY2015
July 30, 2014
-
REGULATORY MHLW to Review Criteria for Clinical Research Core Hospitals by April
July 29, 2014
-
BUSINESS AbbVie Hopes to Make Humira Major Drug for Biologics-Naïve Patients: President
July 28, 2014
-
ORGANIZATION JPMA President Hints at Adoption of Unified System to Disclose Fees Paid to Doctors Next Year
July 25, 2014
-
BUSINESS Ono, BMS Announce Strategic Alliance for 5 Immuno-Oncology Products
July 25, 2014
-
BUSINESS Astellas Gears Up to Accelerate R&D
July 24, 2014
-
REGULATORY Chain Pharmacies’ Drug Price Settlement Rate in June Triples from 2 Years Ago
July 23, 2014
-
BUSINESS Disclosure of Payments from Drug Makers to Doctors Delayed
July 22, 2014
-
BUSINESS Carna Shooting for 1st Licensing Deal on Kinase Inhibitor in 2014
July 18, 2014
-
BUSINESS Merck Serono Japan Hopes to Boost Erbitux Share by Narrowing Down CRC Patients: President
July 17, 2014
-
BUSINESS Ono President Professes High Hopes for Newly Approved Anticancer Drug Opdivo
July 16, 2014
-
BUSINESS Ex-Astellas Chair Sounds Alarm over Oncology-Focused Businesses, Says Govt Finances Will Be Insufficient
July 15, 2014
-
BUSINESS “Favorable Transactions” for Nesp in Return for Support in Clinical Trial: Independent Panel
July 14, 2014
-
REGULATORY Is Legal Regulation Necessary? Clinical Research at Turning Point 1: TRI Director Fukushima
July 14, 2014
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…